Stock Events

Novo Nordisk A/S 

kr873.7
5429
-kr7.9-0.9% Today

Statistics

Day High
888.2
Day Low
864.1
52W High
1,033.2
52W Low
527.3
Volume
2,962,797
Avg. Volume
2,523,565
Mkt Cap
4.04T
P/E Ratio
45.46
Dividend Yield
1.42%
Dividend
12.4

Upcoming

Dividends

1.42%Dividend Yield
10Y Growth
10.67%
5Y Growth
8.76%
3Y Growth
9.87%
1Y Growth
-12.37%

Earnings

2MayConfirmed
Q3 2022
Q4 2022
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
0
2.93
5.85
8.78
Expected EPS
N/A
Actual EPS
5.68

People Also Follow

This list is based on the watchlists of people on Stock Events who follow NOVO-B.CO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sanofi
SNY
Mkt Cap128.21B
Sanofi competes directly with Novo Nordisk in the diabetes and insulin markets, offering similar products and therapies.
Lilly(Eli) &
LLY
Mkt Cap814.94B
Eli Lilly is a major competitor in the diabetes care market, particularly in insulin and GLP-1 receptor agonists, directly competing with Novo Nordisk's portfolio.
Astrazeneca
AZN
Mkt Cap244.04B
AstraZeneca competes in the diabetes sector with its range of type 2 diabetes medications, posing competition to Novo Nordisk's diabetes care products.
Merck &
MRK
Mkt Cap318.55B
Merck is a competitor in the diabetes market with its drug Januvia among others, competing with Novo Nordisk's diabetes management products.
Bristol-Myers Squibb
BMY
Mkt Cap86.44B
Bristol Myers Squibb competes in the area of diabetes and cardiovascular diseases, areas where Novo Nordisk also has a significant presence.
Pfizer
PFE
Mkt Cap169.83B
Pfizer competes with Novo Nordisk in various therapeutic areas, including chronic diseases, though not as directly in diabetes.
Novartis
NVS
Mkt Cap232.42B
Novartis competes across a broad range of therapeutic areas including cardiovascular, which overlaps with Novo Nordisk's interests.
Johnson & Johnson
JNJ
Mkt Cap372.29B
Johnson & Johnson, through its pharmaceutical division Janssen, competes in several areas including diabetes care.
Abbott Laboratories
ABT
Mkt Cap177.49B
Abbott Laboratories competes with Novo Nordisk in the broader healthcare market, including diabetes management through its glucose monitoring devices.
Thermo Fisher Scientific
TMO
Mkt Cap203.97B
Thermo Fisher Scientific competes indirectly by providing instruments and reagents for diabetes research, affecting the market landscape.

About

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Show more...
CEO
Mr. Lars Fruergaard Jorgensen
Employees
66015
Country
DK
ISIN
DK0060534915
WKN
000A1XA8R

Listings